TW200503729A - Treating androgen deficiency in female (ADIF)-associated conditions with SARMS - Google Patents
Treating androgen deficiency in female (ADIF)-associated conditions with SARMSInfo
- Publication number
- TW200503729A TW200503729A TW093101758A TW93101758A TW200503729A TW 200503729 A TW200503729 A TW 200503729A TW 093101758 A TW093101758 A TW 093101758A TW 93101758 A TW93101758 A TW 93101758A TW 200503729 A TW200503729 A TW 200503729A
- Authority
- TW
- Taiwan
- Prior art keywords
- female
- adif
- subject
- treating
- sarm
- Prior art date
Links
- 206010002261 Androgen deficiency Diseases 0.000 title abstract 2
- 229940083324 Selective androgen receptor modulator Drugs 0.000 abstract 4
- 239000000849 selective androgen receptor modulator Substances 0.000 abstract 4
- 150000001204 N-oxides Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000013078 crystal Substances 0.000 abstract 2
- -1 hydrate Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010058359 Hypogonadism Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 208000010428 Muscle Weakness Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 208000024963 hair loss Diseases 0.000 abstract 1
- 230000003676 hair loss Effects 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 208000001076 sarcopenia Diseases 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44130803P | 2003-01-22 | 2003-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200503729A true TW200503729A (en) | 2005-02-01 |
Family
ID=32771915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093101758A TW200503729A (en) | 2003-01-22 | 2004-01-27 | Treating androgen deficiency in female (ADIF)-associated conditions with SARMS |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050032750A1 (enExample) |
| EP (1) | EP1594490A4 (enExample) |
| JP (1) | JP2006516286A (enExample) |
| CN (1) | CN1771031A (enExample) |
| AU (1) | AU2004206909A1 (enExample) |
| CA (1) | CA2514024A1 (enExample) |
| TW (1) | TW200503729A (enExample) |
| WO (1) | WO2004064747A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759520B2 (en) | 1996-11-27 | 2010-07-20 | University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
| US20060019931A1 (en) * | 2003-10-14 | 2006-01-26 | Dalton James T | Treating bone-related disorders with selective androgen receptor modulators |
| US8445534B2 (en) | 2000-08-24 | 2013-05-21 | University Of Tennessee Research Foundation | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs |
| US20040260108A1 (en) * | 2001-06-25 | 2004-12-23 | Dalton James T. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
| CN1726020A (zh) * | 2002-10-16 | 2006-01-25 | Gtx公司 | 用sarm治疗老年男性雄激素缺乏(adam)相关的疾病 |
| US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| FI20030958A0 (fi) * | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
| US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
| CA2626337C (en) | 2005-10-19 | 2015-12-29 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| KR100785038B1 (ko) * | 2006-04-17 | 2007-12-12 | 삼성전자주식회사 | 비정질 ＺｎＯ계 ＴＦＴ |
| ES2780193T3 (es) * | 2006-07-12 | 2020-08-24 | Univ Tennessee Res Found | Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina |
| US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| AU2007287070C1 (en) | 2006-08-24 | 2013-02-14 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
| US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| US8791158B2 (en) | 2010-01-11 | 2014-07-29 | Gtx, Inc. | Methods of treating meibomian gland dysfunction |
| FR2982261B1 (fr) * | 2011-11-04 | 2014-06-13 | Galderma Res & Dev | Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US12685719B2 (en) | 2012-07-13 | 2026-07-21 | University Of Tennessee Research Foundation | Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| EP3733170A1 (en) * | 2012-07-13 | 2020-11-04 | Oncternal Therapeutics, Inc. | A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| CA2965372C (en) | 2014-10-22 | 2023-09-05 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| CA3002562A1 (en) | 2015-10-22 | 2017-04-27 | Havah Therapeutics Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| CN106405064B (zh) * | 2016-08-30 | 2018-10-26 | 嘉兴行健生物科技有限公司 | 一种40岁以上女性骨转换率的评估方法 |
| CN114599369B (zh) | 2019-06-03 | 2026-02-10 | 哈瓦赫治疗有限公司 | 用于递送雄激素剂和芳香酶抑制剂的药物制剂和系统以及使用方法 |
| US11701332B2 (en) | 2020-11-18 | 2023-07-18 | Bryce Nicholas Day | Methods and compositions for treating female sexual interest and arousal disorder |
| US20230172897A1 (en) * | 2021-12-02 | 2023-06-08 | Veru, Inc. | Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents |
| CN122228246A (zh) * | 2023-11-16 | 2026-06-16 | 恩多凯医药科技（北京）有限公司 | 神经活性雄激素受体调节剂及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8617653D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
| EP0635015B1 (en) * | 1992-04-10 | 1997-01-29 | Pfizer Inc. | Acylaminoindole derivatives as 5-ht1 agonists |
| US6569896B2 (en) * | 2000-08-24 | 2003-05-27 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
| US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| WO2003074449A2 (en) * | 2002-02-28 | 2003-09-12 | University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
| WO2003074473A2 (en) * | 2002-02-28 | 2003-09-12 | University Of Tennessee Research Foundation | Irreversible selective androgen receptor modulators and methods of use thereof |
| AU2003241583B2 (en) * | 2002-06-17 | 2009-05-21 | University Of Tennessee Research Foundation | N-bridged selective androgen receptor modulators and methods of use thereof |
| EP1562594A4 (en) * | 2002-10-15 | 2008-12-17 | Univ Tennessee Res Foundation | SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH METHYLENE BRIDGES AND METHOD OF USE THEREOF |
-
2004
- 2004-01-20 EP EP04703606A patent/EP1594490A4/en not_active Withdrawn
- 2004-01-20 AU AU2004206909A patent/AU2004206909A1/en not_active Abandoned
- 2004-01-20 CN CNA2004800077667A patent/CN1771031A/zh active Pending
- 2004-01-20 WO PCT/US2004/001359 patent/WO2004064747A2/en not_active Ceased
- 2004-01-20 CA CA002514024A patent/CA2514024A1/en not_active Abandoned
- 2004-01-20 US US10/759,538 patent/US20050032750A1/en not_active Abandoned
- 2004-01-20 JP JP2006501034A patent/JP2006516286A/ja active Pending
- 2004-01-27 TW TW093101758A patent/TW200503729A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004064747A3 (en) | 2005-01-27 |
| AU2004206909A1 (en) | 2004-08-05 |
| CN1771031A (zh) | 2006-05-10 |
| JP2006516286A (ja) | 2006-06-29 |
| AU2004206909A2 (en) | 2004-08-05 |
| EP1594490A2 (en) | 2005-11-16 |
| US20050032750A1 (en) | 2005-02-10 |
| CA2514024A1 (en) | 2004-08-05 |
| WO2004064747A2 (en) | 2004-08-05 |
| EP1594490A4 (en) | 2006-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004064747A3 (en) | Treating androgen deficiency in female (adif)-associated conditions with sarms | |
| CA2538095A1 (en) | Selective androgen receptor modulators and methods of use thereof | |
| TW200407280A (en) | N-bridged selective androgen receptor modulators and methods of use thereof | |
| WO2004035737A3 (en) | Heterocyclic selective androgen receptor modulators and methods of use thereof | |
| WO2004035738A3 (en) | Methylene-bridged selective androgen receptor modulators and methods of use thereof | |
| EP1487458A4 (en) | MULTI-SUBSTITUTED ANDROGEN SELECTIVE RECEPTOR MODULATORS AND METHODS AND USES THEREOF | |
| WO2003074449A3 (en) | Multi-substitued selective androgen receptor modulators and methods of use thereof | |
| WO2005113565A3 (en) | Metabolites of selective androgen receptor modulators and methods of use thereof | |
| TW200502250A (en) | Treating androgen decline in aging male (ADAM)-associated conditions with SARMS | |
| WO2004062612A3 (en) | Large-scale synthesis of selective androgen receptor modulators | |
| WO2003074473A3 (en) | Irreversible selective androgen receptor modulators and methods of use thereof | |
| SI1902026T1 (sl) | Derivati tetrahidrokarbazola uporabni kot modulatorji androgenskega receptorja | |
| PT1891038E (pt) | N-arilpirrolidinas substituídas como moduladores selectivos do receptor de androgénio | |
| EP4699660A3 (en) | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders | |
| MX356271B (es) | Composiciones de alquilglicósido para administracion de farmacos. | |
| WO2009140448A8 (en) | Tetrahydrocyclopenta[b]indole androgen receptor modulators | |
| JO2800B1 (en) | Rosaclubta tetrahydrate compounds [B] indole androgen regulators | |
| WO2005037201A3 (en) | Treating bone-related disorders with selective androgen receptor modulators | |
| MA34046B1 (fr) | Ligands sigma pour potentialiser l'effet analgésique d'opioïdes et d'opiacés dans une douleur post-opératoire et atténuer la dépendance à ceux-ci | |
| WO2007081696A3 (en) | Treating androgen decline in aging male (adam)-associated conditions with sarms | |
| TW200716662A (en) | Process for making fluorinated 4-azasteroid derivatives | |
| TW200512204A (en) | A method of treating breast cancer with androgen receptor antagonists |